Cas:81-78-7 2-[[5-(2-carboxyanilino)-9,10-dioxoanthracen-1-yl]amino]benzoic acid manufacturer & supplier

Chemical Name:2-[[5-(2-carboxyanilino)-9,10-dioxoanthracen-1-yl]amino]benzoic acid

CAS.NO:81-78-7

Synonyms:N,N’-(9,10-Dioxo-9,10-dihydro-anthracen-1,5-diyl)-di-anthranilsaeure;2,2′-[(9,10-dihydro-9,10-dioxo-1,5-anthrylene)diimino]bisbenzoic acid;Anthraquinone-1,5-bis-anthranilic acid;1,5-Bis(2-carboxyanilino)anthraquinone;1.5-Bis-(2-carboxy-anilino)-anthrachinon;1,5-Bis(2-carboxyanilino)-9,10-anthracenedione;Acridylic Acid;Vulcan Violet BN;N,N’-(9,10-dioxo-9,10-dihydro-anthracene-1,5-diyl)-di-anthranilic acid;Violet BN Acid Anthraquinone

Molecular Formula:C₂₈H₁₈N₂O₆

Molecular Weight:478.45200

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:730.7ºC at 760 mmHg

Density:1.513g/cm3

Index of Refraction:1.769

PSA:132.80000

Exact Mass:478.11600

LogP:5.49160

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N,N’-(9,10-Dioxo-9,10-dihydro-anthracen-1,5-diyl)-di-anthranilsaeure chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Violet BN Acid Anthraquinone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Acridylic Acid Use and application,N,N’-(9,10-dioxo-9,10-dihydro-anthracene-1,5-diyl)-di-anthranilic acid technical grade,usp/ep/jp grade.

Related News: Beta Bionics is committed to obtaining regulatory approval and commercializing all three iLet configurations. 2-[[5-(2-carboxyanilino)-9,10-dioxoanthracen-1-yl]amino]benzoic acid manufacturer Advanced clinical trials with the Company��s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS. 2-[[5-(2-carboxyanilino)-9,10-dioxoanthracen-1-yl]amino]benzoic acid supplier Beta Bionics is committed to obtaining regulatory approval and commercializing all three iLet configurations. 2-[[5-(2-carboxyanilino)-9,10-dioxoanthracen-1-yl]amino]benzoic acid vendor One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. 2-[[5-(2-carboxyanilino)-9,10-dioxoanthracen-1-yl]amino]benzoic acid factory Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access.